A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP)

Farimani, Marzie; Heshmati, Safoura; Poorolajal, Jalal; Bahmanzadeh, Maryam

doi:10.1007/s11033-019-04609-w

Cited by 65 publications

(50 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite the fact that no association was demonstrated between PRP components and any tumor promotion [79], and that the intense cell proliferation events entailed may induce malignancy was voiced [55]. Although there is no evidence demonstrating any side effects regarding PRP application in the reproductive system, we may be far from reassuring patients on long-term safety [31][32][33][34][35]54,55].…”

Section: Discussionmentioning

confidence: 99%

“…As a result, oxygen, nutrients, and hormonal supply is interrupted and follicular growth is compromised. However, studies indicate that this condition may be reversible and follicular growth could be stimulated when the jeopardized ovarian microenvironment is restored [31][32][33][34][35][53][54][55].…”

Section: Discussionmentioning

confidence: 99%

“…The radical concept of autologous intraovarian PRP ovaries infusion was pioneered [ 30 , 31 ], with the intent to revive ovarian function in perimenopausal women. Thenceforth, various attempts were documented entailing autologous intraovarian PRP infusion in POR patients [ 32 , 33 ], in menopausal and in POI women [ 34 , 35 ], demonstrating its promising role in infertility management. Albeit PRP has not established routine clinical status yet, it has emerged as an option in addressing ovarian insufficiency.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Sfakianoudis¹,

Simopoulou

Grigoriadis

et al. 2020

JCM

View full text Add to dashboard Cite

Intraovarian platelet-rich plasma (PRP) infusion was recently introduced in the context of addressing ovarian insufficiency. Reporting on its effectiveness prior to adopting in clinical routine practice is imperative. This study aims to provide pilot data regarding PRP application for ovarian rejuvenation. Four pilot studies were conducted on poor ovarian response (POR), premature ovarian insufficiency (POI), perimenopause, and menopause, respectively. Each pilot study reports on thirty patients, 120 participants were recruited in total. All participants provided written informed consent prior to treatment. Primary outcome measures for the POR pilot study were levels of anti-müllerian hormone (AMH), antral follicle count (AFC) and oocyte yield. For the POI, perimenopausal and menopausal pilot studies primary outcome measures were restoration of menstrual cycle, and Follicle Stimulating Hormone (FSH) levels. A significant improvement on the hormonal profile and the ovarian reserve status was noted, along with improved intracytoplasmic sperm injection (ICSI) cycle performance concerning POR participants. Menstruation recovery was observed in 18 out of 30 POI patients, along with a statistically significant improvement on levels of AMH, FSH, and AFC. Similarly, 13 out of 30 menopausal women positively responded to PRP treatment. Finally, menstruation regularity, improved hormonal levels and AFC were reported for 24 out of 30 perimenopausal women. To conclude, PRP infusion appears to convey promising results in addressing ovarian insufficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Sfakianoudis¹,

Simopoulou

Grigoriadis

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…These effects might be due to an increased in ovarian vascularization, with a key role in ovarian function as well as in promoting follicle development increasing follicular cell proliferation and survival ( 95 ). After this first report, ovarian and endocrine positive effects and live births have been also reported in several series of patients with impaired ovarian function such as POR ( 127 ) and POI women ( 130 , 134 ).…”

Section: The Prp Approachmentioning

confidence: 85%

Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency

2021

View full text Add to dashboard Cite

Premature ovarian insufficiency is a common disorder affecting young women and represents the worst-case ovarian scenario due to the substantial impact on the reproductive lifespan of these patients. Due to the complexity of this condition, which is not fully understood, non-effective treatments have yet been established for these patients. Different experimental approaches are being explored and strategies based on stem cells deserve special attention. The regenerative and immunomodulatory properties of stem cells have been successfully tested in different tissues, including ovary. Numerous works point out to the efficacy of stem cells in POI treatment, and a wide range of clinical trials have been developed in order to prove safety and effectiveness of stem cells therapy—in diminished ovarian reserve and POI women. The main purpose of this review is to describe the state of the art of the treatment of POI involving stem cells, especially those that use mobilization of stem cells or paracrine signaling.

show abstract

“…For perimenopausal and prematurely menopausal IVF patients of poor ovarian reserve, the reported results showed restoration of ovarian function along with restoration of the menstrual cycle post treatment [ 108 ]. On the other hand, data on poor responder patients similarly indicate an impressive hormonal improvement, improved oocyte yield, clinical pregnancies and subsequent live births in a short time interval post PRP treatment [ 117 , 119 ]. Two recent published studies provide data in regard to PRP’s effectiveness in addressing POR, indicating that PRP may be an effective solution towards enhancing IVF/ICSI outcomes for both young and older POR patients [ 17 , 120 ].…”

Section: Managing Poor Ovarian Responsementioning

confidence: 99%

The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment

et al. 2020

View full text Add to dashboard Cite

Despite recent striking advances in assisted reproductive technology (ART), poor ovarian response (POR) diagnosis and treatment is still considered challenging. Poor responders constitute a heterogeneous cohort with the common denominator of under-responding to controlled ovarian stimulation. Inevitably, respective success rates are significantly compromised. As POR pathophysiology entails the elusive factor of compromised ovarian function, both diagnosis and management fuel an ongoing heated debate depicted in the literature. From the criteria employed for diagnosis to the plethora of strategies and adjuvant therapies proposed, the conundrum of POR still puzzles the practitioner. What is more, novel treatment approaches from stem cell therapy and platelet-rich plasma intra-ovarian infusion to mitochondrial replacement therapy have emerged, albeit not claiming clinical routine status yet. The complex and time sensitive nature of this subgroup of infertile patients indicates the demand for a consensus on a horizontally accepted definition, diagnosis and subsequent effective treating strategy. This critical review analyzes the standing criteria employed in order to diagnose and aptly categorize POR patients, while it proceeds to critically evaluate current and novel strategies regarding their management. Discrepancies in diagnosis and respective implications are discussed, while the existing diversity in management options highlights the need for individualized management.

show abstract

A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP)

Cited by 65 publications

References 38 publications

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women

Stem Cell Paracrine Signaling for Treatment of Premature Ovarian Insufficiency

The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment

Contact Info

Product

Resources

About